Homozygous familial hypercholesterolemia with resistance to Inclisiran (siRNA PCSK9i) - a case report

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Heterozygous type 1 familial hypercholesterolemia patient with a rare LDL receptor mutation and the efficacy of evolocumab in the management of consequent hyperlipidemia2024
2. 2Failure of lipid control by <scp>PCSK9</scp> inhibitors in compound heterozygous familial hypercholesterolemia complicated with premature myocardial infarction: A case report2024 · 8 citations
3. 3PCSK9 targeting therapies for familial hypercholesterolaemia: a meta-analysis of efficacy on lipid biomarkers and safety in adults and children across 23 RCTs2025 · 9 citations
4. 4Assessing the Impact of Inclisiran on LDL-C and PCSK9 Reduction in Hypercholesterolemic Patients: A Meta-analysis of Cardiovascular Metabolic Prevention2026
5. 5Challenges in the management of familial hypercholesterolemia: a case report2024